Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
IPI-ASAC Brasil is a specialized pharmaceutical company and the Brazilian subsidiary of the Spanish group ASAC Pharma. The company is dedicated to the field of allergy and immunology, focusing on the production and distribution of allergen-specific immunotherapy (allergy vaccines) and diagnostic tools. Their product range includes subcutaneous and sublingual treatments tailored to individual patient sensitivities, particularly for respiratory allergies like asthma and rhinitis. IPI-ASAC Brasil provides clinical support and high-quality biological products to healthcare professionals across Brazil. The company leverages the research and development capabilities of its parent organization to maintain a leading position in the Brazilian allergy market. Their operations are centered on providing personalized medicine solutions for allergic diseases.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on IPI-ASAC Brasil.